Decisions by ICER and NICE discordant for some cancer drugs

  • PDF / 171,490 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 41 Downloads / 175 Views

DOWNLOAD

REPORT

866-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 14 Nov 2020 No. 866

1

Data Loading...

Recommend Documents
ICERs for diagnostics and factors impacting NICE decisions

175 35 182KB

ICER

138 90 57MB

NICE evaluations of drugs, medical devices and diagnostics

167 48 164KB

NICE has increased its capacity for appraising new drugs and treatments, and will be able to review existing NICE apprai

159 93 133KB

ICER favours vinorelbine + cisplatin for NSCLC

180 102 120KB

Nice Numbers

192 57 12MB

NICE recommendations submitted by Kennedy

178 73 138KB

Drugs in Clinical Development for Breast Cancer

117 77 195KB

Drugs for HER-2-positive Breast Cancer

101 61 1MB

Drugs in Clinical Development for Prostate Cancer

172 96 179KB

Non-targeted Drugs for Cancer Therapy

210 75 41MB

ICER news September 2020

184 70 171KB